CCS1477
PreclinicalSmall molecule
CCS1477 is one of 19 small molecule programs targeting Haematological Malignancy. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Haematological Malignancy
#DrugCompanyPhaseTrials
1Venclexta
AbbViePreclinical
Ninlaro
TakedaPreclinical
Tecvayli
Johnson & JohnsonPreclinical
Darzalex
Johnson & JohnsonPreclinical
Alecensa
RochePreclinical
Tecentriq
RochePreclinical
Rozlytrek
RochePreclinical
Tabrecta
NovartisPreclinical
Tafinlar
NovartisPreclinical
Mekinist
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CCS1477. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CCellCentric Ltd.